Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q2 2022 Earnings Presentation
15 slides from Heartbeam's earnings presentation, Aug 11, 2022
Slide 1: Heart Attack Detection
Heart Attack Detection Second Quarter 2022 Financial Results Conference Call NASDAQ: BEAT August 11, 2022
Slide 2: Disclaimers
Second Quarter 2022 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial positio
Slide 3: Agenda
Second Quarter 2022 Financial Results Conference Call Agenda • Introduction and Recent Announcements Branislav Vajdic • Product Timelines and Updates, and Partnerships Jon Hunt • Model at Scale and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic 30 years of experience 34 years’
Slide 4: Key Second Quarter 2022 and Subsequent Highlights
Second Quarter 2022 Financial Results Conference Call Key Second Quarter 2022 and Subsequent Highlights • 510(k) application for HeartBeam AIMI™ platform to FDA to aid in diagnosis of heart attack to be submitted imminently, with expected clearance in the coming months and limited market release by
Slide 5: ED Software Tool Updates
Second Quarter 2022 Financial Results Conference Call ED Software Tool Updates • Submission of HeartBeam AIMI™ platform to FDA to aid in diagnosis of heart attack on or about August 15, with expected clearance in the fourth quarter and limited market release by end of 2022 • Partnered with LIVMOR In
Slide 6: HeartBeam AIMI Software Product First Revenues
Second Quarter 2022 Financial Results Conference Call HeartBeam AIMI™ Software Product First Revenues HeartBeam’s software-only heart attack diagnosis tool for the ED Software licensing business model improves accuracy of MI diagnosis drives $100k/year per ED 93% No change in ED GEN 1 patient workfl
Slide 7: Revenue Opportunity: TAM $500m and $10bn
Second Quarter 2022 Financial Results Conference Call HeartBeam AIMI™ Software and Gen. 1 HeartBeam AIMIGo™ Revenue Opportunity HeartBeam AIMI™ HeartBeam AIMI™ GEN 1 HeartBeam AIMIGo™ HeartBeam SOFTWARE SOLUTION HeartBeam will use its own salesforce AIMIGo™ HeartBeam will use its own salesforce Exce
Slide 8: HeartBeam AIMIGo Updates
Second Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo™ Updates • Partnered with Triple Ring Technologies to co-develop its HeartBeam AIMIGo™ complete solution 3D vector Electrocardiogram (ECG) collection device for remote heart attack (MI) monitoring Q2 2022 Q3 2022 Q4 2022 Q1 2023
Slide 9: HeartBeam AIMIGo Product Development and Regulatory Plan
Second Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo™ Product Development and Regulatory Plan 3D Vector Cardiogram FDA 510(K) HeartBeam Credit card sized AIMIGo™ collection device Predicate devices identified GEN 1 Smartphone app Simple validation study Synthesized baseline + Q3 20
Slide 10: HeartBeam AIMIGo Product Reimbursement Strategy
Second Quarter 2022 Financial Results Conference Call HeartBeam AIMIGo™ Product Reimbursement Strategy Use Available RPM Codes to Accelerate Revenue and Data Collection Utilize existing RPM* Codes Basic Gen 1 CPT Codes Description MPFS** Remote monitoring of physiologic Excellent alignment with 9945
Slide 11: Market Landscape: Substantial Capabilities Beyond Existing Offerings
Second Quarter 2022 Financial Results Conference Call Market Landscape Substantial Capabilities Beyond Existing Offerings Heart Attack Detection 12L ECG Capable Integrates history & symptoms Uses Baseline Long Term Use Potential AFib Detection AFlutter Detection 11
Slide 12: Sample Financial Model at Scale
Second Quarter 2022 Financial Results Conference Call Sample Financial Model for our HeartBeam AIMI™ & HeartBeam AIMIGo™ Solutions at Scale Revenue at TAM Penetration % Sample Financial Model $25M Sample Financial Model $100M $ in Thousands HeartBeam AIMI™ HeartBeam AIMIGo™ Total HeartBeam AIMI™ Hea
Slide 13: Q2 2022 Financial Highlights
Second Quarter 2022 Financial Results Conference Call Q2 2022 Financial Highlights $ in Thousands Quarters ended June 30, 2022 2021 Operating Expenses: General & Administrative $1,793 $312 Research & Development 1,742 25 Total Operating Expenses 3,535 337 Loss from Operations (3,535) (337) Interest
Slide 14: Closing Summary
Second Quarter 2022 Financial Results Conference Call Closing Summary • Well known and previously unsolved problem with a massive worldwide market • Product timeline and milestones on track for FDA Clearance and market launch • HeartBeam AIMI™ platform pending submission to FDA to aid in diagnosis o
Slide 15: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050